For the remaining four of the 15 genes, including FBF1, CNIH2, TMEM121, and MAMDC4, there are hardly any documents concerning their potential roles in cancer development, thus providing potentially novel candidates for understanding how deslanoside inhibits tumor growth in prostate cancer. This evidence concerns the gene FBF1 and Familial prostate cancer.